Tagworks Pharmaceuticals

Delivering a new class of ADCs and targeted radionuclide therapies for solid tumors with our proprietary Click-to-Release treatment platform

[Tagworks Pharmaceuticals @Tagworkspharma]

We are excited to announce the initiation of our Phase 0/1 clinical trial, sponsored by @radboudumc , evaluating TGW211 in patients with #HER2positive #tumors. Learn more: https://t.co/5oVSE4UBzz

[Tagworks Pharmaceuticals @Tagworkspharma]

On #WorldCancerResearchDay, we’re reminded that bold scientific innovation is essential. Hear from Marc Robillard, PhD, Tagworks’ co-founder and CSO, about how we’re advancing pioneering in vivo click chemistry into a new standard of care for patients with #solidtumors.

[Tagworks Pharmaceuticals @Tagworkspharma]

We’re excited to announce that the third dose level has been initiated in our ongoing Phase 1 clinical trial evaluating our lead #ADC program TGW101 in patients with advanced #solidtumors.

Learn more: https://t.co/HnbQmzH5uE

[Tagworks Pharmaceuticals @Tagworkspharma]

We’re innovating for patients with #solidtumors so they can have safer, more effective therapies. Developed with our pioneering Click-to-Release approach, our lead #oncology #ADC program called TGW101 is now recruiting for a #clinicaltrial. Learn more: https://t.co/KsLxQ6AIO9

[Tagworks Pharmaceuticals @Tagworkspharma]

We’re proud to be featured in a #NatureBiotechnology profile on #radiopharmaceuticals! Our Click-to-Release treatment platform shows potential to remove dose-limiting toxicities to more safely and effectively treat #solidtumors. Read here: https://t.co/G7jKgaSsmY

[Tagworks Pharmaceuticals @Tagworkspharma]

At #AACR2025, we presented preclinical data on the potential of our Click-to-Release treatment platform to enable safe, tolerable, and potent delivery of therapeutic candidates for #solidtumors. View the posters: https://t.co/Oz7IOuAiNe
#ADCs #oncology

[Tagworks Pharmaceuticals @Tagworkspharma]

We’re excited to welcome Keith Orford, MD, PhD, as our new CMO! His leadership in #oncology research and clinical drug development will be invaluable as we transition to the clinic. Learn more: https://t.co/oqUs33OsVm

[Tagworks Pharmaceuticals @Tagworkspharma]

We’re thrilled to announce the initiation of our Phase 1 clinical trial evaluating TGW101, an #ADC developed with our Click-to-Release treatment platform, in patients with advanced #solidtumors. Learn more: https://t.co/EKirGtjYvH

[Tagworks Pharmaceuticals @Tagworkspharma]

We look forward to attending #AACR2025! We will share preclinical data that demonstrate the potential of our pioneering Click-to-Release platform to improve the standard of care for patients with #solidtumor #cancers. Learn more: https://t.co/ImKcu4xv12 #ADCs #oncology

[Tagworks Pharmaceuticals @Tagworkspharma]

We're excited to announce Ken Mills has been appointed our new CEO and that Marc Robillard will continue as CSO & Board member. We look forward to working to bring our Click-to-Release platform and lead ADC program for solid tumors into the clinic in 2025. https://t.co/RFcVYuXonc

[Tagworks Pharmaceuticals @Tagworkspharma]

Proud to have won the second place for this years LSX Lifestars Awards - Series A of the Year. Great recognition for @Tagworkspharma and our fantastic group of investors !
Congrats to Complement Tx and Adcendo and thanks to @lifestarsawards for this great night out !

[ChemEurJ: Chemistry - A European Journal @ChemEurJ]

A concise synthetic approach to highly reactive click-to-release trans-cyclooctene linkers (Robillard et al. @Tagworkspharma) https://t.co/CaxGRAzOsr

[Jordi Xiol @jordixiol]

‘Clicked’ drugs: researchers prove the remarkable chemistry in humans

Featuring @Tagworkspharma

#portfolio

https://t.co/ckDX4c2ZXl

[Tagworks Pharmaceuticals @Tagworkspharma]

@NEA Thank you @NEA, Michele Park and James Buxton, for supporting the mission of @Tagworkspharma to deliver click-cleavable ADCs and other therapies to the clinic !

[Tagworks Pharmaceuticals @Tagworkspharma]

@RoeyJAmir thank you Roey !

[Tagworks Pharmaceuticals @Tagworkspharma]

@GildeHealthcare thank you @Gildehealthcare for co-leading this great round for #Tagworkspharma !

[Tagworks Pharmaceuticals @Tagworkspharma]

@YsiosCapital @EIF_EU @icfcat Thank you Thomas and the whole Ysios team for leading this fantastic round !

[Tagworks Pharmaceuticals @Tagworkspharma]

@Click_Chemist thank you Dennis !

[Tagworks Pharmaceuticals @Tagworkspharma]

We’re excited to announce that we’ve raised $65 Million in Series A financing to advance a pipeline of Click-to-Release Therapeutics ! https://t.co/TKTHHZVGLy

[Tagworks Pharmaceuticals @Tagworkspharma]

@PhosphorusFive thank you Christian !!

[C2W @Chem2W]

Het Nederlandse @Tagworkspharma heeft een grote investeringsronde met succes afgesloten. De financiële impuls biedt het bedrijf de middelen om klinische studies met de belangrijkste kandidaat-ADC in gang te zetten: https://t.co/sOrPXuypfj